BIOA
HealthcareBioAge Labs, Inc. · Biotechnology · $630M
What is BioAge Labs, Inc.?
BioAge Labs is a clinical-stage biopharmaceutical company focused on metabolic diseases, using a proprietary aging-biology platform to discover and develop novel drug candidates. The company is headquartered in Emeryville, California.
BioAge Labs applies insights from human aging biology to identify drug targets for metabolic and inflammatory diseases. Its lead candidate, azelaprag, is an orally available small molecule being evaluated for obesity treatment, including a combination study with tirzepatide in older adults. The company also advances BGE-100, a brain-penetrant small molecule targeting neuroinflammation. Revenue is not yet generated from product sales — the company is funded through capital raises typical of clinical-stage biotechs.
BioAge Labs was incorporated in 2015 and is based in Emeryville, California.
- Azelaprag — oral small molecule in obesity clinical trials
- Azelaprag plus tirzepatide combination study in older adults
- BGE-100 — NLRP3 antagonist targeting neuroinflammation
- Proprietary human aging dataset and target-discovery platform
Is BIOA a Good Stock to Buy?
UQS Score rates BIOA as Poor overall, reflecting the early-stage nature of the business and meaningful financial and pipeline risks.
The Growth pillar stands out as the relative bright spot, capturing the potential upside embedded in BioAge's clinical pipeline and the large addressable market for obesity and metabolic disease treatments. The Risk pillar lands at Neutral, suggesting the company's risk profile is not extreme relative to other clinical-stage peers.
Both the Quality and Moat pillars are rated Weak, consistent with a pre-revenue company that lacks durable competitive advantages or established financial performance. Valuation is rated Elevated, meaning the current price already reflects considerable optimism about pipeline success.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account on UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BIOA pay dividends?
No — BioAge Labs, Inc. does not currently pay a dividend.
BioAge Labs does not pay a dividend. As a clinical-stage company with no product revenue, capital is directed entirely toward research, clinical trials, and operations. Income-focused investors should not expect distributions in the near term — reinvestment into pipeline advancement is the company's primary use of funds.
When does BIOA report earnings?
BioAge Labs reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly results center on operating expenses, cash runway, and pipeline milestones rather than sales or profit trends. Investors typically focus on clinical trial updates and cash position disclosures.
For the most recent quarter's results and upcoming reporting schedule, visit BioAge Labs' investor relations page directly.
BIOA Price History
-5.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in BioAge Labs, Inc.?
Based on BioAge Labs, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
BIOA Long-term Outlook
BioAge Labs' fundamental outlook is shaped by the binary nature of clinical-stage drug development. The Good Growth pillar rating reflects genuine pipeline optionality — particularly in the obesity space, which has attracted significant industry attention. However, the Elevated Valuation pillar and Weak Quality pillar signal that the market may already be pricing in favorable outcomes, leaving limited margin for setbacks. The Neutral Risk rating suggests the company is not uniquely fragile, but clinical trial risk remains the dominant variable.
Growth drivers
- Advancing azelaprag through obesity clinical trials, including the tirzepatide combination study
- Expanding the BGE-100 neuroinflammation program toward later-stage development
- Leveraging the proprietary aging-biology platform to identify additional drug targets
Key risks
- Clinical trial failure or disappointing efficacy data for lead candidates
- Elevated valuation leaving little room for pipeline disappointments
- Ongoing cash consumption with no product revenue to offset operating costs
BIOA vs Peers
BioAge Labs operates in a competitive clinical-stage biotech landscape alongside several small-cap peers pursuing distinct therapeutic approaches.
Solid Biosciences focuses on gene therapy for Duchenne muscular dystrophy, a rare disease area distinct from BioAge's metabolic and aging-biology focus.
Eton Pharmaceuticals targets rare pediatric diseases with a commercialization-stage model, contrasting with BioAge's earlier-stage pipeline.
Prime Medicine pursues prime editing gene correction technology across a range of genetic diseases, representing a different scientific platform from BioAge's small-molecule aging approach.
Frequently Asked Questions
What does BioAge Labs do?
BioAge Labs is a clinical-stage biopharmaceutical company that uses human aging biology to discover treatments for metabolic diseases. Its lead program, azelaprag, targets obesity, and it also develops BGE-100 for neuroinflammation. The company has no approved products and generates no product revenue at this stage.
Does BIOA pay dividends?
No, BioAge Labs does not pay a dividend. The company is pre-revenue and directs all available capital toward clinical development and operations. A dividend is unlikely until the company reaches commercial-stage profitability, which is not anticipated in the near term.
When does BIOA report earnings?
BioAge Labs reports on a quarterly cadence standard for US-listed companies. Because our data source does not cover specific upcoming dates, check the company's investor relations page for the current reporting schedule and most recent results.
Is BIOA a good stock to buy?
UQS Score rates BIOA as Poor overall. The Growth pillar shows pipeline potential, but Weak Quality and Moat ratings alongside an Elevated Valuation suggest meaningful risk. Whether BIOA fits a portfolio depends on an investor's risk tolerance and view on clinical trial outcomes. The full pillar breakdown is available to Pro members.
Is BIOA overvalued?
The UQS Valuation pillar for BIOA is rated Elevated, indicating the current market price reflects considerable optimism about pipeline success. For a pre-revenue clinical-stage company, valuation is inherently speculative and tied to trial outcomes rather than current financial performance.
How does BIOA compare to its competitors?
BioAge Labs competes in the small-cap clinical-stage biotech space alongside companies like Solid Biosciences, Eton Pharmaceuticals, and Prime Medicine. Each pursues different therapeutic areas and scientific platforms. UQS Score provides side-by-side pillar comparisons for Pro members looking to evaluate these peers systematically.
What is BIOA's market cap bracket?
BioAge Labs is classified as a small-cap company. This is typical for clinical-stage biotechs that have gone public before reaching commercial revenue, and it reflects the early position of the company in its development lifecycle.
Who founded BioAge Labs?
BioAge Labs was founded by Kristen Fortney, who serves as CEO, and Eric Morgen. The company was incorporated in 2015 and went public to fund its clinical-stage pipeline in metabolic and aging-related diseases. Further founding details are available through public company filings.
Is BIOA a long-term quality investment?
From a long-term quality standpoint, BIOA's UQS Score is rated Poor, with Weak Quality and Moat pillars reflecting the absence of established financial performance or durable competitive advantages. Long-term quality indicators favor companies with proven business models — BioAge's long-term case rests entirely on clinical success.
What is the main competitive advantage of BioAge Labs?
BioAge's differentiation lies in its proprietary human aging dataset and target-discovery platform, which the company uses to identify drug candidates based on molecular changes associated with aging. However, the UQS Moat pillar is rated Weak, reflecting that this advantage has not yet translated into durable commercial barriers.
What sector does BIOA belong to?
BioAge Labs operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. The company's focus on metabolic diseases and aging biology places it in a segment that has attracted significant investor and industry attention in recent years.
Is BIOA a growth stock or value stock?
Based on UQS pillar ratings, BIOA leans toward growth — the Growth pillar is rated Good, reflecting pipeline optionality. However, the Valuation pillar is Elevated, meaning investors are already paying a premium for that potential. It does not exhibit the characteristics of a traditional value stock.
Unlock Full BIOA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics and trend data
- ✓Compare BIOA against clinical-stage biotech peers
- ✓Track Quality, Moat, and Valuation signals over time
- ✓Get the full analyst view available to Pro members
Pro Analysis
BIOA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 18.8 | 1.3 | 13.0 | 37.9 | 51.1 | 0.0 | -3.5 |
| May 11, 2026 | 22.3 | 1.3 | 13.0 | 55.4 | 51.1 | 0.0 | +0.2 |
| May 10, 2026 | 22.1 | 0.0 | 13.0 | 55.4 | 51.8 | 0.0 | -0.7 |
| Apr 22, 2026 | 22.8 | 1.3 | 13.0 | 55.4 | 54.3 | 0.0 | -2.8 |
| Apr 2, 2026 | 25.6 | 1.3 | 13.0 | 69.2 | 54.3 | 0.0 | — |
BIOA — Pillar Breakdown
Quality
— 1.3/100 (25%)BioAge Labs, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 37.9/100 (20%)BioAge Labs, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 51.1/100 (15%)BioAge Labs, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)BioAge Labs, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 13/100 (25%)BioAge Labs, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BIOA.
Score Composition
Financial Data
More Stock Analysis
How is the BIOA UQS Score Calculated?
The UQS (Unified Quality Score) for BioAge Labs, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses BioAge Labs, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether BioAge Labs, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.